Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drug
Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at (...)
Site référencé: The Economic Times
The Economic Times
IndusInd accounting lapse row : CEO's exit may point to more issues, hit recovery, margins
30/04/2025
US auto tariff relief brings temporary respite for OEMs, but uncertainty looms : Jay Kale
30/04/2025
Ather Energy IPO crosses the line in final hours of Day 3 ; retail portion booked 1.55 times
30/04/2025
Varun Beverages Q4 results : PAT rises 33% YoY, revenue surges 29%
30/04/2025
The golden illusion : Know the risks behind gold’s safe haven image
30/04/2025
HAL, GRSE and other defence stocks fall up to 5% on profit booking amid India-Pakistan tensions
30/04/2025
